Cellectis to Announce Q3 2024 Financial Results Soon
Cellectis, a clinical-stage biotechnology company known for its innovative gene-editing technology, has informed stakeholders that it will release its financial results for the third quarter of 2024 shortly after the close of the US market. This report will cover the period ending September 30, 2024, marking a significant moment for the company, which is trading under the ticker CLLS on the Nasdaq.
Details of the Upcoming Earnings Release
The financial results will be followed by an investor conference call scheduled for the next day. During this call, Cellectis will not only present its quarterly results but also provide updates on its business activities and strategic direction.
Conference Call Information
Investors interested in participating can call in using the following numbers:
- Domestic: +1-800-225-9448
- International: +1-203-518-9708
For reference, the Conference ID for this call is CLLSQ3. A webcast will also be available for those who prefer to join online.
About Cellectis
Founded with a pioneering approach in the biotechnology field, Cellectis focuses on developing groundbreaking therapies through its proprietary gene-editing platform. The company emphasizes an allogeneic strategy particularly notable in CAR-T cell therapies, aiming to provide off-the-shelf solutions to treat various types of cancer.
Innovative Technologies and Solutions
Cellectis utilizes its TALEN® technology for gene editing, combined with the PulseAgile platform that enhances its capabilities in therapeutic gene editing and immune system modulation. This dual approach not only aims to treat cancer but also addresses diseases that currently lack effective therapies.
Track Record and Expansion
With a robust background of 25 years in the field of gene editing, Cellectis is well-positioned to address unmet medical needs through its cutting-edge research and product development. The company's headquarters in Paris complements its operational presence in New York and Raleigh, enhancing its capacity for innovation.
As a publicly traded entity on both the Nasdaq (CLLS) and Euronext Growth (ALCLS), Cellectis is dedicated to transparency and stakeholder engagement, evident in its upcoming financial disclosures.
Contact Information for Inquiries
Cellectis encourages interested parties to reach out for further information through its dedicated communication channels.
Media Inquiries:
Pascalyne Wilson, Director of Communications
+33 (0)7 76 99 14 33
Investor Relations:
Arthur Stril, Interim Chief Financial Officer
+1 (347) 809 5980
For additional details, please send communications to media@cellectis.com or investors@cellectis.com.
Frequently Asked Questions
What is the date of Cellectis' Q3 2024 earnings report?
Cellectis will report its Q3 2024 financial results on November 4, 2024.
When will the investor conference call take place?
The investor conference call is scheduled for November 5, 2024, at 8:00 AM ET.
How can investors participate in the conference call?
Investors can join by calling the domestic number +1-800-225-9448 or the international number +1-203-518-9708, using Conference ID CLLSQ3.
What technology does Cellectis use in its therapies?
Cellectis employs TALEN® technology and the PulseAgile platform for its gene editing and CAR-T cell therapies.
Where is Cellectis headquartered?
Cellectis is headquartered in Paris, France, with additional offices in New York and Raleigh.
